Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Private Equity | Alive

Total Raised


Last Raised

$150K | 15 yrs ago

About In Silico Scientifics

Provider of drug discovery research in the area of diseases associated with insulin resistance, such as type 2 diabetes, obesity, and metabolic syndrome.

In Silico Scientifics Headquarters Location

In Silico Scientifics 116 Research Drive

Bethlehem, Pennsylvania, 18015,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing In Silico Scientifics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

In Silico Scientifics is included in 1 Expert Collection, including Diabetes.



1,750 items

  • Where is In Silico Scientifics's headquarters?

    In Silico Scientifics's headquarters is located at In Silico Scientifics, Bethlehem.

  • What is In Silico Scientifics's latest funding round?

    In Silico Scientifics's latest funding round is Private Equity.

  • How much did In Silico Scientifics raise?

    In Silico Scientifics raised a total of $150K.

  • Who are the investors of In Silico Scientifics?

    Investors of In Silico Scientifics include Ben Franklin/Progress.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.